A Phase Ib Open-Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Bevacizumab and Immunotherapy When Administered in Patients With Gastrointestinal and Other Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Roche
- 28 Sep 2017 Planned End Date changed from 14 Sep 2018 to 15 Aug 2019.
- 28 Sep 2017 Planned primary completion date changed from 14 Sep 2018 to 15 Dec 2018.
- 03 Oct 2016 Status changed from not yet recruiting to recruiting.